Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:07 AM
Study NCT ID:
NCT00046397
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
2002-09-27
Brief Title:
Phase I Trial of Smallpox Vaccine
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
A Phase III Clinical Trial of Modified Vaccinia Virus Ankara MVA to Evaluate Its Safety Dosing Schedule Immunogenicity and Protective Efficacy Against Dryvax Challenge in Vaccinia-Naive Individuals
Status:
COMPLETED
Status Verified Date:
2005-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will test the safety of an experimental vaccine called Modified Vaccinia Virus Ankara MVA for use against the smallpox virus It will also investigate how many injections of MVA are needed to produce immunity against vaccinia virus which is closely related to the smallpox virus An effective smallpox vaccine exists but it can cause side effects that on rare occasions can be life-threatening The FDA gave new license approval for Dryvax on 102502 but has not been used in the general population since smallpox was eradicated worldwide Both the MVA and Dryvax Registered Trademark vaccines are made using the vaccinia virus however the MVA vaccine contains a more attenuated or weakened form of the virus httpwwwfdagovcberproductssmalwye102502htm
Healthy normal volunteers between 18 and 30 years of age who have never been vaccinated with a smallpox vaccine may be eligible for this study Candidates will be screened with a medical history physical examination and blood and urine tests including an HIV test and a pregnancy test for women of childbearing potential
MVA placebo and Dryvax Registered Trademark will be administered by different methods The MVA vaccine and placebo are injected into an arm muscle with a needle and syringe The Dryvax Registered Trademark vaccine is administered as it was for many years with a special forked needle that is poked lightly into the skin of the upper arm usually 15 times in a process called scarification When the vaccine works a small pus-filled blister forms followed by a scab and then scarring at the site of the vaccination The formation of the blister and scab is called a take indicating that the vaccine is effective and is evidence of the development of immunity The development of a take suggests that an individual will be protected against smallpox for at least a few years If scarification does not take it can either mean that the person already has immunity or that the vaccine did not work
Participants will be assigned to groups as well as product randomly For instance the first study participant could be enrolled into group 3 The Dryvax Registered Trademark dose is given as a challenge to see if the person has a take A reduced take response or no take could suggest that MVA is able to produce an immune response The dosing schedules vary from 12 to 24 weeks and volunteers are in the study a total of 24 to 36 weeks depending on the number of injections
Participants will be observed for at least 1 hour after each injection They will come to the clinic a week after MVA or placebo injections and at least twice a week after Dryvax Registered Trademark for about 21 days to have the injection site evaluated and photographed At each visit participants will be asked about how they are feeling and if they are taking any medications Blood and urine tests will be done on injection days and at follow up visits scheduled 1 and 4 weeks after each immunization as well as 12 weeks after the Dryvax Registered Trademark challenge dose Additional tests may be done between visits if medically necessary
Healthy normal volunteers between 18 and 30 years of age who have never been vaccinated with a smallpox vaccine may be eligible for this study Candidates will be screened with a medical history physical examination and blood and urine tests including an HIV test and a pregnancy test for women of childbearing potential
MVA placebo and Dryvax Registered Trademark will be administered by different methods The MVA vaccine and placebo are injected into an arm muscle with a needle and syringe The Dryvax Registered Trademark vaccine is administered as it was for many years with a special forked needle that is poked lightly into the skin of the upper arm usually 15 times in a process called scarification When the vaccine works a small pus-filled blister forms followed by a scab and then scarring at the site of the vaccination The formation of the blister and scab is called a take indicating that the vaccine is effective and is evidence of the development of immunity The development of a take suggests that an individual will be protected against smallpox for at least a few years If scarification does not take it can either mean that the person already has immunity or that the vaccine did not work
Participants will be assigned to groups as well as product randomly For instance the first study participant could be enrolled into group 3 The Dryvax Registered Trademark dose is given as a challenge to see if the person has a take A reduced take response or no take could suggest that MVA is able to produce an immune response The dosing schedules vary from 12 to 24 weeks and volunteers are in the study a total of 24 to 36 weeks depending on the number of injections
Participants will be observed for at least 1 hour after each injection They will come to the clinic a week after MVA or placebo injections and at least twice a week after Dryvax Registered Trademark for about 21 days to have the injection site evaluated and photographed At each visit participants will be asked about how they are feeling and if they are taking any medications Blood and urine tests will be done on injection days and at follow up visits scheduled 1 and 4 weeks after each immunization as well as 12 weeks after the Dryvax Registered Trademark challenge dose Additional tests may be done between visits if medically necessary
Detailed Description:
Phase III randomized placebo-controlled double-blinded schedule finding study of MVA The hypothesis is that MVA will be safe in humans when administered by intramuscular IM injection and will result in an immune response comparable to that observed after Dryvax primary vaccination The primary objectives include evaluating the safety of MVA administered by intramuscular IM injection on single and multidose schedules and identifying a schedule of MVA that provides clinical evidence of protection against vaccinia Dryvax challenge The secondary objectives are to compare the immunogenicity of Dryvax and MVA as measured by vaccinia-specific neutralizing antibody ELISA and intracellular cytokines assays and by a variola-specific neutralizing antibody assay that will be conducted at the CDC on a subset of samples
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 02-I-0316 | None | None | None |